Drug interactions for elderly with respiratory disorders and times of COVID-19: a systematic scoping review
DOI:
https://doi.org/10.17533/udea.vitae.v27n3a02Keywords:
Coronavirus Infections, Contraindications Drug, Drug-Related Effects and Adverse Reactions, Inappropriate Prescribing, Older Adults, Potentially Inappropriate Medication List, Patient Safety, Respiratory Tract DiseasesAbstract
Background: The elderly people have high morbimortality associated with respiratory disorders, in addition to the presence of other safety risk factors, such as the use of potentially inappropriate medication and the occurrence of drug interactions. Objective: Considering the current pandemic scenario, it was intended to identify explicit criteria-based tools that reported drug interactions between potentially inappropriate medication and respiratory system disorders and possibly worse prognosis of COVID-19 infection. Methods: A systematic scoping review was conducted until February 2020. Study characteristics of explicit criteria-based tools, and potentially inappropriate medication, drug interactions, and therapeutic management, were extracted. Results: Nineteen explicit criteria-based tools were included. Nineteen drug interactions and 17 potentially inappropriate medications with concerns for three respiratory disorders (asthma, chronic pulmonary obstructive disease, and respiratory failure) were identified. The most frequent pharmacological classes reported were benzodiazepines and beta-blockers. For clinical management, the tools recommend using cardioselective beta-blockers, calcium channel blockers, angiotensin-converting enzyme inhibitors, and angiotensin II type I receptor blockers, and benzodiazepines with a short or intermediate half-life. Conclusion: Considering the increased risk of COVID-19 infection in the elderly, drug interactions and the use of potentially inappropriate medication associated with the occurrence of adverse drug events in the respiratory system may also worsening COVID-19 infection in patients with uncontrolled respiratory disorders. Thus, it is essential to assess drug therapy in use, to identify safety risks, and monitor the elderly in general and those with a worse prognosis concerning COVID-19, promoting patient safety.
Downloads
References
Angus DC. Current and Projected Workforce Requirements for Care of the Critically Ill and Patients With Pulmonary Disease. JAMA. 2000 Dec 6;284(21):2762. DOI: https://doi.org/10.1001/jama.284.21.2762
Thanaviratananich S, Cho S-H, Ghoshal AG, Muttalif ARBA, Lin H-C, Pothirat C, et al. Burden of respiratory disease in Thailand: Results from the APBORD observational study. Medicine (Baltimore). 2016 Jul;95(28):e4090. DOI: https://doi.org/10.1097/MD.0000000000004090
Wang DY, Ghoshal AG, Bin Abdul Muttalif AR, Lin H-C, Thanaviratananich S, Bagga S, et al. Quality of Life and Economic Burden of Respiratory Disease in Asia-Pacific—Asia-Pacific Burden of Respiratory Diseases Study. Value Heal Reg Issues. 2016 May;9:72–7. DOI: https://doi.org/10.1016/j.vhri.2015.11.004
Carreiro-Martins P, Gomes-Belo J, Papoila AL, Caires I, Palmeiro T, Gaspar-Marques J, et al. Chronic respiratory diseases and quality of life in elderly nursing home residents. Chron Respir Dis. 2016 Aug;13(3):211–9. DOI: https://doi.org/10.1177/1479972316636990
Shahid Z, Kalayanamitra R, McClafferty B, Kepko D, Ramgobin D, Patel R, et al. COVID‐19 and Older Adults: What We Know. J Am Geriatr Soc [Internet]. 2020 May 20;68(5):926–9. DOI: https://doi.org/10.1111/jgs.16472
Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis. 2020 May;94:91–5. DOI: https://doi.org/10.1016/j.ijid.2020.03.017
von der Thüsen J, Eerden M. Histopathology and genetic susceptibility in COVID‐19 pneumonia. Eur J Clin Invest. 2020 Jul 27;50(7):eci.13259. DOI: https://doi.org/10.1111/eci.13259
Arentz M, Yim E, Klaff L, Lokhandwala S, Riedo FX, Chong M, et al. Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State. JAMA. 2020 Apr 28;323(16):1612. DOI: https://doi.org/10.1001/jama.2020.4326
Lake MA. What we know so far: COVID-19 current clinical knowledge and research. Clin Med (Northfield Il). 2020 Mar;20(2):124–7. DOI: https://doi.org/10.7861/clinmed.2019-coron
Tadic M, Cuspidi C, Mancia G, Dell’Oro R, Grassi G. COVID-19, hypertension and cardiovascular diseases: Should we change the therapy? Pharmacol Res. 2020 Aug;158:104906. DOI: https://doi.org/10.1016/j.phrs.2020.104906
O Riordan D, Aubert CE, Walsh KA, Van Dorland A, Rodondi N, Du Puy RS, et al. Prevalence of potentially inappropriate prescribing in a subpopulation of older European clinical trial participants: a cross-sectional study. BMJ Open. 2018 Mar 22;8(3):e019003. DOI: https://doi.org/10.1136/bmjopen-2017-019003
Wehling M. Multimorbidity and polypharmacy: how to reduce the harmful drug load and yet add needed drugs in the elderly? Proposal of a new drug classification: fit for the aged. J Am Geriatr Soc. 2009 Mar;57(3):560–1. DOI: https://doi.org/10.1111/j.1532-5415.2009.02131.x.
Forgerini M, Herdeiro MT, Galduróz JCF, Mastroianni P de C. Sao Paulo Med J. 2020 Jun;138(3):216–8. Risk factors associated with drug therapy among elderly people with Alzheimer’s disease: a cross-sectional study. DOI: https://doi.org/10.1590/1516-3180.2019.0461.r2.19022020
Varallo FR, Costa MA, Mastroianni P de C. Potenciais interações medicamentosas responsáveis por internações hospitalares. Rev Ciencias Farm Basica e Apl. 2013;
Mastroianni P de C, Forgerini M. Compliance and Drug Related Problems in probable Alzheimer’s disease elderly. Int Psychogeriatrics. 2019;1–2. DOI: https://doi.org/10.1017/S104161021800234X
Komagamine J. Prevalence of potentially inappropriate medications at admission and discharge among hospitalised elderly patients with acute medical illness at a single centre in Japan: a retrospective cross-sectional study. BMJ Open. 2018 Jul 19;8(7):e021152. DOI: https://doi.org/10.1136/bmjopen-2017-021152
Almeida; LS de, Nascimento; MMG do, Oliveira; DR de, Oliveira; I V., Detoni; LB, Caux; TR de, et al. Potentially inappropriate medication use profile among older people with chronic obstructive pulmonary disease. Rev Ciências da Saúde Básica e Apl. 2019;2:29–42.
Forgerini M, Schiavo G, Lucchetta RC, Mastroianni P de C. Drug interactions for elderly people with mental and behavioral disorders: a systematic scoping review. Arch Gerontol Geriatr. 2020; DOI: https://doi.org/10.1016/j.archger.2020.104283
The Joanna Briggs Institute. Summary for Policymakers. In: Intergovernmental Panel on Climate Change, editor. Climate Change 2013 - The Physical Science Basis. Cambridge: Cambridge University Press; 2015. p. 1–30.
Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ WV (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). [Internet]. 2019. Available from: https://training.cochrane.org/handbook
Tricco AC, Lillie E, Zarin W, O’Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018 Oct 2;169(7):467.
Schiavo G, Lucchetta RC, Forgerini M, Mastroianni P de C. Assessment tool for potentially inappropriate medication use in the elderly: a scoping review protocol. Rev Ciências Farm Básica e Apl. 2018;39:e637.
Lucchetta R. Potentially inappropriate medications criteria-based tools for the elderly: a systematic scoping review. OSF. 2020; DOI: https://doi.org/10.17605/OSF.IO/EUVR2
Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020 Apr;8(4):e21. DOI: https://doi.org/10.1016/S2213-2600(20)30116-8
Guan W, Liang W, Zhao Y, Liang H, Chen Z, Li Y, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. 2020 May;55(5):2000547. DOI: https://doi.org/10.1183/13993003.00547-2020
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar;395(10229):1054–62. DOI: https://doi.org/10.1016/S0140-6736(20)30566-3
Chen Y, Guo Y, Pan Y, Zhao ZJ. Structure analysis of the receptor binding of 2019-nCoV. Biochem Biophys Res Commun. 2020 Apr;525(1):135–40. DOI: https://doi.org/10.1016/j.bbrc.2020.02.071
Williams B, Zhang Y. Hypertension, renin–angiotensin–aldosterone system inhibition, and COVID-19. Lancet. 2020 May;395(10238):1671–3. DOI: https://doi.org/10.1016/S0140-6736(20)31131-4
Reynolds HR, Adhikari S, Pulgarin C, Troxel AB, Iturrate E, Johnson SB, et al. Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Covid-19. N Engl J Med. 2020 May 1;NEJMoa2008975. DOI: https://doi.org/10.1056/NEJMoa2008975
Bean; DM, Kraljevic; Zeljko, Searle; T, Bendayan; R, Pickles1; A, Folarin; A, et al. Treatment with ACE-inhibitors is associated with less severe disease with SARS-Covid-19 infection in a multi-site UK acute Hospital Trust. medRxiv. 2020; DOI: https://doi.org/10.1101/2020.04.07.20056788
de Abajo FJ, Rodríguez-Martín S, Lerma V, Mejía-Abril G, Aguilar M, García-Luque A, et al. Use of renin–angiotensin–aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study. Lancet. 2020 May;395(10238):1705–14. DOI: https://doi.org/10.1016/S0140-6736(20)31030-8
Salpeter SR, Ormiston TM, Salpeter EE. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005 Oct 19; DOI: https://doi.org/10.1002/14651858.CD003566.pub2
Morales DR, Jackson C, Lipworth BJ, Donnan PT, Guthrie B. Adverse Respiratory Effect of Acute β-Blocker Exposure in Asthma. Chest. 2014 Apr;145(4):779–86. DOI: https://doi.org/10.1378/chest.13-1235
Duffy S, Marron R, Voelker H, Albert R, Connett J, Bailey W, et al. Effect of beta-blockers on exacerbation rate and lung function in chronic obstructive pulmonary disease (COPD). Respir Res. 2017 Dec 19;18(1):124. DOI: https://doi.org/10.1186/s12931-017-0609-7
Morales DR, Lipworth BJ, Donnan PT, Jackson C, Guthrie B. Respiratory effect of beta-blockers in people with asthma and cardiovascular disease: population-based nested case control study. BMC Med. 2017 Dec 27;15(1):18. DOI: https://doi.org/10.1186/s12916-017-0781-0
Hernandez A V., Roman YM, Pasupuleti V, Barboza JJ, White CM. Hydroxychloroquine or Chloroquine for Treatment or Prophylaxis of COVID-19: A Living Systematic Review. Ann Intern Med. 2020 May;M20-2496. DOI: https://doi.org/10.7326/M20-2496
Patel TK, Barvaliya M, Kevadiya BD, Patel PB, Bhalla HL. Does Adding of Hydroxychloroquine to the Standard Care Provide Any Benefit in Reducing the Mortality Among COVID-19 Patients?: A Systematic Review. J Neuroimmune Pharmacol. 2020; DOI: https://doi.org/10.1007/s11481-020-09930-x
Al-Bari MAA. Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases. J Antimicrob Chemother. 2015 Jun 1;70(6):1608–21. DOI: https://doi.org/10.1093/jac/dkv018
Juurlink DN. Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection. Can Med Assoc J [Internet]. 2020 Apr 27;192(17):E450–3. Available from: http://www.cmaj.ca/lookup/doi/10.1503/cmaj.200528
Mascolo A, Berrino PM, Gareri P, Castagna A, Capuano A, Manzo C, et al. Neuropsychiatric clinical manifestations in elderly patients treated with hydroxychloroquine: a review article. Inflammopharmacology. 2018 Oct 9;26(5):1141–9. DOI: https://doi.org/10.1007/s10787-018-0498-5
Ross SB, Wilson MG, Papillon‐Ferland L, Elsayed S, Wu PE, Battu K, et al. COVID‐SAFER: Deprescribing Guidance for Hydroxychloroquine Drug Interactions in Older Adults. J Am Geriatr Soc. 2020 Aug 30;68(8):1636–46. DOI: https://doi.org/10.1111/jgs.16623
Kroll DS, Nieva HR, Barsky AJ, Linder JA. Benzodiazepines are Prescribed More Frequently to Patients Already at Risk for Benzodiazepine-Related Adverse Events in Primary Care. J Gen Intern Med. 2016 Sep 13;31(9):1027–34. DOI: https://doi.org/10.1007/s11606-016-3740-0
Baillargeon J, Singh G, Kuo Y-F, Raji MA, Westra J, Sharma G. Association of Opioid and Benzodiazepine Use with Adverse Respiratory Events in Older Adults with Chronic Obstructive Pulmonary Disease. Ann Am Thorac Soc. 2019 Oct;16(10):1245–51. DOI: https://doi.org/10.1513/AnnalsATS.201901-024OC.
Nakafero G, Sanders RD, Nguyen-Van-Tam JS, Myles PR. Association between benzodiazepine use and exacerbations and mortality in patients with asthma: a matched case-control and survival analysis using the United Kingdom Clinical Practice Research Datalink. Pharmacoepidemiol Drug Saf. 2015 Aug;24(8):793–802. DOI: https://doi.org/10.1002/pds.3799
Lucchetta RC, da Mata BPM, Mastroianni P de C. Association between Development of Dementia and Use of Benzodiazepines: A Systematic Review and Meta-Analysis. Pharmacother J Hum Pharmacol Drug Ther. 2018 Oct;38(10):1010–20. DOI: https://doi.org/10.1002/phar.2170
Scichilone N. Comorbidities of Lung Disease in the Elderly. Clinics in Geriatric Medicine. 2017. DOI: https://doi.org/10.1016/j.cger.2017.06.010.
Leal LF, Bertoldi AD, Menezes AMB, Borges RB, Mengue SS, Gazzana MB, et al. Indicação, acesso e utilização de medicamentos para doenças respiratórias crônicas no Brasil: resultados da Pesquisa Nacional sobre Acesso, Utilização e Promoção do Uso Racional de Medicamentos no Brasil (PNAUM), 2014. Cad Saude Publica. 2018 Oct 11;34(10). DOI: https://doi.org/10.1590/0102-311x00208217
Scichilone N, Ventura MT, Bonini M, Braido F, Bucca C, Caminati M, et al. Choosing wisely: practical considerations on treatment efficacy and safety of asthma in the elderly. Clin Mol Allergy. 2015 Dec 22;13(1):7. DOI: https://doi.org/10.1186/s12948-015-0016-x
Mäkelä MJ, Backer V, Hedegaard M, Larsson K. Adherence to inhaled therapies, health outcomes and costs in patients with asthma and COPD. Respir Med. 2013 Oct;107(10):1481–90. DOI: https://doi.org/10.1016/j.rmed.2013.04.005
Muir J-F, Lamia B, Molano C, Cuvelier A. Respiratory Failure in the Elderly Patient. Semin Respir Crit Care Med. 2010 Oct 12;31(05):634–46. DOI: https://doi.org/10.1055/s-0030-1265903.
Shoemaker SJ, Ramalho de Oliveira D. Understanding the meaning of medications for patients: The medication experience. Pharm World Sci. 2007 Nov 21;30(1):86–91. DOI: https://doi.org/10.1007/s11096-007-9148-5
O’Mahony D, Gallagher P, Lavan A. Methods to reduce prescribing errors in elderly patients with multimorbidity. Clin Interv Aging. 2016 Jun;11:857. DOI: https://doi.org/10.2147/CIA.S80280
Dills H, Shah K, Messinger-Rapport B, Bradford K, Syed Q. Deprescribing Medications for Chronic Diseases Management in Primary Care Settings: A Systematic Review of Randomized Controlled Tri
als. J Am Med Dir Assoc. 2018 Nov;19(11):923-935.e2. DOI: https://doi.org/10.1016/j.jamda.2018.06.021
Gabe ME, Murphy F, Davies GA, Russell IT, Jordan S. Medication Monitoring in a Nurse-Led Respiratory Outpatient Clinic: Pragmatic Randomised Trial of the West Wales Adverse Drug Reaction Profile. Scheurer M, editor. PLoS One. 2014 May 5;9(5):e96682. DOI: https://doi.org/10.1371/journal.pone.0096682
Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH. Updating the Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. Arch Intern Med. 2003 Dec 8;163(22):2716. DOI: https://doi.org/10.1001/archinte.163.22.2716
Winit-Watjana W, Sakulrat P, Kespichayawattana J. Criteria for high-risk medication use in Thai older patients. Arch Gerontol Geriatr. 2008 Jul;47(1):35–51. DOI: https://doi.org/10.1016/j.archger.2007.06.006
Kim DS, Heo SI, Lee SH. Development of a List of Potentially Inappropriate Drugs for the Korean Elderly Using the Delphi Method. Healthc Inform Res. 2010;16(4):231. DOI: https://doi.org/10.4258/hir.2010.16.4.231
Mimica Matanović S, Vlahovic-Palcevski V. Potentially inappropriate medications in the elderly: a comprehensive protocol. Eur J Clin Pharmacol. 2012 Aug 24;68(8):1123–38. DOI: https://doi.org/10.1007/s00228-012-1238-1
Mann E, Böhmdorfer B, Frühwald T, Roller-Wirnsberger RE, Dovjak P, Dückelmann-Hofer C, et al. Potentially inappropriate medication in geriatric patients: the Austrian consensus panel list. Wien Klin Wochenschr. 2012 Mar 2;124(5–6):160–9. DOI: https://doi.org/10.1007/s00508-011-0061-5
Fialová D. Potentially Inappropriate Medication Use Among Elderly Home Care Patients in Europe. JAMA. 2005 Mar 16;293(11):1348. DOI: https://doi.org/10.1001/jama.293.11.1348.
Clyne B, Bradley MC, Hughes CM, Clear D, McDonnell R, Williams D, et al. Addressing potentially inappropriate prescribing in older patients: development and pilot study of an intervention in primary care (the OPTI-SCRIPT study). BMC Health Serv Res. 2013 Dec 14;13(1):307. DOI: https://doi.org/10.1186/1472-6963-13-307
Delgado Silveira E, Montero Errasquín B, Muñoz García M, Vélez-Díaz-Pallarés M, Lozano Montoya I, Sánchez-Castellano C, et al. Mejorando la prescripción de medicamentos en las personas mayores: una nueva edición de los criterios STOPP-START. Rev Esp Geriatr Gerontol. 2015 Mar;50(2):89–96. DOI: https://doi.org/10.1016/j.regg.2014.10.005
O’Mahony D, O’Sullivan D, Byrne S, O’Connor MN, Ryan C, Gallagher P. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2014 Oct 16;44(2):213–8. DOI: https://doi.org/10.1093/ageing/afu145
Tommelein E, Petrovic M, Somers A, Mehuys E, van der Cammen T, Boussery K. Older patients’ prescriptions screening in the community pharmacy: development of the Ghent Older People’s Prescriptions community Pharmacy Screening (GheOP3S) tool. J Public Health (Bangkok). 2016 Jun;38(2):e158–70. DOI: https://doi.org/10.1093/pubmed/fdv090
Renom-Guiteras A, Meyer G, Thürmann PA. The EU(7)-PIM list: a list of potentially inappropriate medications for older people consented by experts from seven European countries. Eur J Clin Pharmacol. 2015 Jul 14;71(7):861–75. DOI: https://doi.org/10.1007/s00228-015-1860-9
Kojima T, Mizukami K, Tomita N, Arai H, Ohrui T, Eto M, et al. Screening Tool for Older Persons’ Appropriate Prescriptions for Japanese: Report of the Japan Geriatrics Society Working Group on “Guidelines for medical treatment and its safety in the elderly.” Geriatr Gerontol Int. 2016 Sep;16(9):983–1001. DOI: https://doi.org/10.1111/ggi.12890
Poudel A, Ballokova A, Hubbard RE, Gray LC, Mitchell CA, Nissen LM, et al. Algorithm of medication review in frail older people: Focus on minimizing the use of high-risk medications. Geriatr Gerontol Int. 2016 Sep;16(9):1002–13. DOI: https://doi.org/10.1111/ggi.12589
Oliveira MG, Amorim WW, Oliveira CRB, Coqueiro HL, Gusmão LC, Passos LC. Consenso brasileiro de medicamentos potencialmente inapropriados para idosos. Geriatr Gerontol Aging. 2017 Dec;10(4):168–81. DOI: https://doi.org/10.5327/Z2447-211520161600054
Kim M-Y, Etherton-Beer C, Kim C-B, Yoon JL, Ga H, Kim HC, et al. Development of a Consensus List of Potentially Inappropriate Medications for Korean Older Adults. Ann Geriatr Med Res. 2018 Sep 30;22(3):121–9. DOI: https://doi.org/10.4235/agmr.2018.22.3.121
Marzi MM, Pires MS, Quaglia NB. Ingredientes Farmacéuticos Activos Potencialmente Inapropiados en Adultos Mayores: Lista IFAsPIAM: Panel de Consenso Argentino. Value Heal Reg Issues. 2018; DOI: https://doi.org/10.1016/j.vhri.2017.10.002
Samaranayake NR, Balasuriya A, Fernando GH, Samaraweera D, Shanika LGT, Wanigasuriya JKP, et al. ‘Modified STOPP-START criteria for Sri Lanka’; translating to a resource limited healthcare setting by Delphi consensus. BMC Geriatr. 2019 Dec 22;19(1):282. DOI: https://doi.org/10.1186/s12877-019-1293-x
Gonzalez-Colaço Harmand M, Aldea-Perona AM, Boada-Fernández del Campo C, Areosa-Sastre A, Rodríguez-Jiménez C, García Sánchez-Colomer M, et al. Spanish list of potentially inappropriate drugs in the elderly (ES-PIA project). Eur J Clin Pharmacol. 2019 Aug 8;75(8):1161–76. DOI: https://doi.org/10.1007/s00228-019-02684-3
Chang C-B, Lai H-Y, Hwang S-J, Yang S-Y, Wu R-S, Chang L-Y, et al. The updated PIM-Taiwan criteria: a list of potentially inappropriate medications in older people. Ther Adv Chronic Dis. 2019 Jan 5;10:204062231987960. DOI: https://doi.org/10.1177/2040622319879602
Published
How to Cite
Issue
Section
License
Copyright (c) 2020 Marcela Forgerini, Geovana Schiavo, Rosa Camila Lucchetta, Patricia Mastroianni
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Copyright Notice and Open Access Statement
The Journal Vitae works under the Open Access license, and the published manuscripts remain available for the public, both on the Journal's website and in databases, under the Creative Commons license, "Noncommercial Attribution" and "Share alike" systems, adopted in Colombia. Hence, when the authors agree to publish in the Journal Vitae, they will not have the right to economic retributions on publications and reproductions through different diffusion media. The documents are freely available to the internet public, permitting users to read, download, copy, distribute, print, search, or link to the full texts and pass them as data to software. The only constraint on reproduction and distribution, should be to give authors control over the integrity of their work and the right to be appropriately acknowledged and cited.
Authors declare that:
-
They are the intellectual property owners and are responsible for all the information stated in the article.
-
This manuscript has not been submitted or published in other printed or digital media. They accept the responsibility for the judgments, opinions, and points of view expressed in the published article and, therefore, they exonerate Universidad de Antioquia and Journal Vitae from any process.
-
They exempt Universidad de Antioquia and Journal Vitae from settling conflicts or disputes related to the authorship of the referred article.
-
They accept the revision of the original manuscript by suitable personnel, and they bind themselves to perform the corrections appointed or suggested by the assessors.
-
Therefore, they know the editorial process and will not bind the Editorial Board of the Journal to assume any obligations regarding the volume and issue in which the article is published.
-
They transfer the rights of publication, reprinting, and distribution of the article from the moment of its approval, in print and digital format, without the right to economic rewards, and under the licensing conditions considered relevant by Journal Vitae.
-
They fully authorize Universidad de Antioquia and Journal Vitae to submit the published material to the diverse databases and indexing systems where the Journal can be found to comply with the requirements of the regulatory authorities to maintain the national classification of journals.
-
They will assume the article publication costs established for the current issue, and they will make the payment as soon as they are informed about the volume and the issue in which the final version of the article is published.
-
After the article is published, you can share digital or printed copies in a noncommercial manner. You will be able to use the paper in your institution or company for educational or research purposes, including the use in course programs.
Conflict of interest: Authors are responsible for recognizing and disclosing any financial or other benefits that could be perceived to bias their work, acknowledging all financial support and any personal connections with potential sponsors. Examples of such conflicts include receiving research funds or honoraria, serving on advisory boards, stock ownership, or employment and consulting arrangements. Authors without such connections should clearly state that they have no financial support or personal relationships that could be perceived to bias their work. All conflicts of interest should be disclosed on the author's identification page of the manuscript.
